Reddit Posts
$GANX with news after months of nothing. Back on the radar
GANX — Honest Look at the Risk Profile. This Is a Binary Clinical Bet With a Ticking Cash Clock.
GANX — The Catalyst Timeline For the Rest of 2026
GANX — Breaking Down the GT-02287 Data. What's Actually Been Shown and What Hasn't.
GANX — Q1 2026 Numbers Out. Here's What Actually Matters.
Standard biotech quarter. No news is news. Watching for Q2.
Loss wider. OpEx higher. Same roadmap. GANX moving forward.
Small sample size on that stability data. Encouraging but not definitive. Phase 2 will separate signal from noise.
GANX Q1: Net loss widened. R&D and G&A up. Timelines intact (Q2 IND, Q3 Phase 2, Q4 more data). That's the real story.
Anyone else following any Parkinsons plays?
GANX Phase 2 in Q3. ANVS has going concern language. AVXL has $131M cash but CHMP rejection. Spread between them is wide. Anyone else tracking these?
Parkinson's Watchlist: Risk breakdown: GANX = early data, high dilution risk. ANVS = late-stage assets, balance sheet stress. AVXL = financial cushion, regulatory uncertainty. Pick your poison.
World Parkinson's Congress right after. Back to back conferences maximize exposure for a small biotech.
My watchlist: VTIX (VR treadmills + defense), GPOX (AI c store distribution), GANX (Parkinson's biotech). Common thread? None are quite there yet.
MJFF backing + Silverstein backing + conference presentations + biomarker data. GANX checking boxes for a clinical stage name.
GANX breakdown: GT-02287 (Parkinson's, GBA1), Phase 1b biomarker data (81% GluSph drop), now two major conferences in May.
$VTIX follow up + new watchlist add ($GANX) – still watching closely
$GANX Announcement - Currently Down 23%
HYPD: Smart debt work. GANX: Early biomarker win. HGRAF: Cool story, rich price.
First-in-class mechanism, Foundation backing, and biomarker validation. GANX stacking quietly.
Parkinson's drug candidate actually moving the needle on spinal fluid biomarkers. GANX worth a look.
Gain Therapeutics ($GANX) - The Parkinson's 'Unicorn' the biotech market is sleeping on. Clinical proof of disease reversal and a major catalyst on 3/17.
Is Gain Therapeutics about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson’s?
Is Gain Therapeutics($GANX) about to make history at AD/PD(3/17) by becoming the first small molecule drug to repair neurons and reverse Parkinson's?
($GANX): March Update- Evidence of Disease Modification Keeps Getting Stronger
$GANX – Massive Parkinson’s Breakthrough? Watch Tomorrow & March 17-21
$GANX – Massive Parkinson’s Breakthrough? Watch Tomorrow & March 17-21
Gain Therapeutics ($GANX) – February 2026 Corporate Deck Update and why this de-risks Phase 2
$GANX - Independent research is validating GT-02287 as likely the first disease-modifying drug for Parkinson's Disease
$GANX- GluSph and rapid clinical benefits and longer-term disease modification
Today's PR and KOL ($GANX- Gain Therapeutics)
Monday DD's are live. As promised.
$GANX Two experts weigh in on GT-02287 and the significance of lowering GluSph
My experience and advice as newbie
$GANX: 10 Reasons why GT-02287 Is Clearly at the Top of the Disease-Modifying Therapy List for Parkinson’s
Where We Are Now With Gain Therapeutics ($GANX) and GT-02287?
$GANX Gain Therapeutics: Final countdown to Phase 1b data at January 6th KOL Event
$GANX- CEO interview just came out-- dispels any misconceptions
$GANX- "The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson’s disease (PD)"
$GANX — Last Call Before Major Data Catalyst (And Still A Buy After)
$GANX Gain Therapeutics Elevator Pitch
"Lightning in a Bottle": "Groundbreaking Early Readout For Gain Therapeutics Gives It A Shot At First Disease-Modifying Drug For Parkinson’s" $GANX
$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)
$GANX — The Most Asymmetric Setup I’ve Ever Seen (And the Clock Is Ticking)
Inflammation: The Common Denominator in Parkinson's Disease ($GANX)
Inflammation: The Common Denominator in Parkinson's Disease ($GANX)
GT-02287 addresses multiple potential sources of Parkinson's ($GANX)
GT-02287 addresses multiple potential sources of Parkinson's ($GANX)
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Gain Therapeutics($GANX) Initial Phase 1b results suggest disease slowing effect in Parkinson’s in just 90 days
Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech.
Gain Therapeutics ($GANX) — quietly emerging as one of the most compelling Parkinson’s stories in biotech.
Gain Therapeutics $GANX Analyst Report highlights 3 unique Parkinson’s Models showing Mitochondrial Benefits
$GANX shows return of smell in Parkinson’s patients - Major December catalysts ahead
GANX Gain Therapeutics with December Parkinson’s Data
My Swan Song: How 20 Years of Grinding Led Me to $GANX
My Swan Song: How 20 Years of Grinding Led Me to $GANX
My Swan Song: How 20 Years of Grinding Led Me to $GANX
$GANX (Gain Therapeutics) Breaking Out, Optimism For Potential First Disease-Modifying Parkinson's Treatment
Most Asymmetric Opportunity in Biotech (and the whole market?) $GANX
Why Gain Therapeutics (GANX) is ready to move
Why Gain Therapeutics (GANX) is ready to move
Gain Therapeutics($GANX) has returned Smell to Parkinson's patients in 2025 and has major catalysts before year end
Gain Therapeutics($GANX) has returned Smell to Parkinson's patients in 2025 and has major catalysts before year end
Gain Therapeutics($GANX) has returned Smell to Parkinson's patients in 2025 and has major catalysts before year end
A Holy Grail of Stocks (explained): Why December Will Likely Redefine the GT-02287 Story (GANX)
(GANX) Gain Therapeutics presented new data today which supports the clinical improvements that it is showing in Parkinson's patients.
Under-the-radar Parkinson’s drug on verge of establishing itself as the most promising treatment to stop disease progression. Likely 10X IMO (GANX)
Mitochondrial Dysfunction a Prime Suspect in Parkinson's: Gain Therapeutics (GANX) address this dysfunction in additional to lysosomal dysfunction
GANX – Gain Therapeutics Is About to Show the Mechanism Behind a True Disease-Modifying PD Drug
GANX Parkinson’s drug, reversing PD symptoms, breaking out. After the low $3’s, I think low $5’s will be next major resistance level.
Parkinson's Drug On Verge Of Historical Data Release (likely acquired at 10X or more in coming month)s: GANX
GANX: a $90 million company becoming a >$900 million company by slowing, stopping, and reversing Parkinson’s disease.
GANX: a $90 million company becoming a >$900 million company by slowing, stopping, and reversing Parkinson’s disease.
GANX: a $90 million company becoming a >$900 million company by slowing, stopping, and reversing Parkinson’s disease.
GANX Parkinson’s treatment returning motor function and sense of smell. Looks to be first ever disease modifying drug for Parkinson’s, and nobody knows it (yet). $75 million MC, likely bought in a few months for $700 million to $1.5 billion (10X-20X)
Gain Therapeutics $GANX Recovered Smell in Parkinson’s patients and will release biomarker data by year end
This $2 biotech might cure Parkinson’s and save Medicare billions. (Ticker: $GANX)
Gain Therapeutics $GANX Recovered Smell in Parkinson’s patients and will release biomarker data by year end
Parkinson’s treatment returning sense of smell and motor function. $75 million MC currently, likely acquired in the next few months (~$1 billion) …GANX
Parkinson’s treatment returning sense of smell and motor function. $75 million MC currently, likely acquired in the next few months (~$1 billion) …GANX
$GANX Gain Therapeutics, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Mentions
Small biotech GANX is supposed to receive IND approval by Wednesday. Could be a fun cheap swing
GANX trading on some nice volume the past week Phase 2 FDA approval expected soon (maybe fast track) Big question how they are going to finance it (they have 16M in cash, burning 5M every quarter); in the past they did ATM offerings, but maybe they can get a strategic partnership (some time) into phase 2 Should be on anyone's watchlist imo
In and observing biotech stocks in following order : CMPX, SLS, GANX
I was looking at GANX this morning as I was contemplating where to put my monthly budget into. I have some token investment in the company (1.7k stocks) and I think their tech is interesting but it is a long and risky play. They have 3-4 quarters left of cash and phase 2 data is probably somewhere in 2027. I might still buy some stocks in the future but for now I think there are better picks in biotech.
GANX hopefully gets IND From FDA soon. Been accumulating and hope it pops to $5-6 by end of year.
Biotechs like ALGS, GANX, LRMR, ABOS. If the company name ends in therapeutics, it could go up a lot.
They will need some financing this year. Market is a drunken sailor stumbling around devoid of all logic. This may or may not ever change. The optimistic thesis is that one can still "discover value" in odd corners - small cap stuff, but even if so, the realization of that value would take many years. I have some money in GANX and some junior Canadian minors right now; otherwise just money markets making 4%.
Late night reflection from an old guy (is 55 old?) with perhaps a rare if not unique perspective. Please bear with me for a moment, I'm going somewhere with this. When I was growing up in the 1970s-80s, the life expectancy for a child born with cystic fibrosis was 5 years. Five years. As late as 2005 only 5 states tested neonates for cystic fibrosis because there wasn't much to do about it: No disease-modifying treatments. Hit them with mucolytics and aggressively manage infections, that's it. I remember seeing a poster when I was a wet-behind-the-years postdoc at a FASEB meeting in the mid-90s by a crappy little company called Vertex Pharma that was trading at several bucks a share. They were trying to develop small molecules to help proteins fold better in diseases like cystic fibrosis and I thought "My goodness THAT is where I should put my money"... except (1) I had almost no money; (2) what money I had I invested in trying to fix my crappy used car and get laid, and (3) I didn't believe in my own financial good judgement. This perhaps was the worst financial mistake I ever made. Fast forward to 2025 when Vertex is a 112 BILLION DOLLAR COMPANY; 4th gen CFTR folding helpers have reached a point where, in the case of the most common CF variant (F508del) the life expectancy of a child who begins taking them by age 15 IS NO DIFFERENT THAN THE POPULATION AVERAGE. Read that again: Kids who would have died at 5 years old when I was a kid are living full lives, getting married, starting businesses, all the good stuff. Because that science worked. Now GANX is doing the SAME CONCEPTUAL THING for Parkinson's disease, with a platform that can feasibly expand to Alzheimer's disease. Don't trust me? Consider from ChatGPT5.2 query "Is there an analogy between the mechanism of action of glucocerebrosidase folding chaperones being developed by Gain pharmaceuticals and the compounds that Vertex developed for cystic fibrosis years ago?" Answer: https://preview.redd.it/c1v7l4cw1hvg1.png?width=1008&format=png&auto=webp&s=597d7ebed9cb97afd8e011b8f978b24f3e0a5318 The risk, of course, is that CNS indications are a much harder proving ground than CF, and financing today is a devilishly harder thing than it was in the 1990s. Nonetheless... Vertex Pharma had about $800 million market cap around 1995. I would have realized a 140-fold gain had I invested in Vertex in the mid 1990s. Now consider: PD market alone is 20-FOLD greater than cystic fibrosis market. Yet literally the same concept: A small molecule that can help a busted protein fold up better and work right. Now consider the initial human studies appear to have arrested disease at least in a subset of PD patients with the right genetic susceptibility. And the $GANX market cap is below $100 million. Wrap your head around that if you will. If Gain is successful, it would imply a 3,000-fold return over 25 years (historical return from Vertex over the same time period x prevalence ratio of PD to cystic fibrosis). $10,000 (two ounces of gold bullion)--> $30,000,000. Sure the risks are high, dilution, logic means diddly-squat in today's market, but if logic means ANYTHING the risk/reward ratio is hugely attractive. In my humble opinion... but not a historically uniformed opinion. The difference now is I can afford to bet tens of thousands of dollars on this horse, and I have, accepting that I may lose it, and any significant capital appreciation likely only will be realized by my kids a couple decades from now. Would you hazard $10K on a couple ounces of gold for an inflation hedge (I have... on more than a couple ounces)? Are you interested in high risk/reward life science technology? If so, this is the place for you.
LASE and GANX seem like interesting stocks. Any thoughts? LASE’s main service/product is using lasers to clean things. In recent months, they’ve been trying to signal their expansion into defense, e.g., a meeting with Congressman Cory Mills —a member of the House Armed Services Committee back in January 2026, and plans to participate in Accelerator Alley SOF week in May 2026 to show off Laser-Shield Anti-Drone system. Also, on 3/18/26, the company released some PR on their site announcing they’re collaborating with Brokk on a laser-cleaning robot for remote nuclear decontamination. Issues: preliminary 2025 financial report from March 10th looked promising, but operating margins and revenue have historically been pretty bad. A lot of money is always being spent on marketing and hiring staff members. Recent warrants. GANX is technically yet another pre-revenue biotech. Their focus is Parkinson’s Disease (PD) and the science looks really good. Lead drug is in Phase 1B. The CEO (Gene Mack) has mentioned a few times not being interested in funding Phase 2 themselves. Regardless of how that plays out, an IND will be submitted soon according to him. The cool thing here is that they discovered the lead drug using their AI-powered drug discovery platform called, “Magellan”. Issues: pre-revenue biotech and all that comes with it.
After posting good news GANX went down bigtime.
Yes, back in November. Here is what my AI has to say: The At-the-Market (ATM) offering for Gain Therapeutics (GANX) is a critical piece of their financial structure that explains why the stock struggles to sustain rallies despite excellent clinical data. As of March 18, 2026, here is the expanded breakdown of the ATM size and its impact: 1. The Total Capacity: $35.5 Million In late November 2025, Gain Therapeutics filed a prospectus supplement for an ATM program totaling up to $35,530,980. * The Mechanism: Unlike a traditional "underwritten" offering where a block of shares is sold all at once at a fixed (usually discounted) price, an ATM allows GANX to sell shares "into the tape" at current market prices whenever they need cash. * The Partner: They are using Oppenheimer & Co. as the sales agent for this program. 2. Relative Size vs. Market Cap To understand why this is a "heavy" offering, look at the proportions: * Market Cap: As of March 2026, GANX has a market cap of approximately $110 million. * Dilution Potential: A $35.5 million offering represents roughly 32% of the company's total value. If the company were to exhaust the entire ATM at current prices (around $2.50–$2.80), they would need to issue roughly 13 to 14 million new shares. * Current Share Count: The company currently has approximately 38.5 million shares outstanding. Fully utilizing the ATM would increase that count by more than a third. 3. Why the ATM is "Capping" the Stock The ATM creates a phenomenon known as an "Overhang." * The Ceiling: Every time the stock price spikes on good news (like today's AD/PD conference data), the company has a massive incentive to sell shares via the ATM to bolster their $8.8 million cash pile. * Market Absorption: When the company sells into a rally, it effectively "soaks up" the buying demand. This is likely why we see "positive news" followed by a flat or downward price move—the company may be using the liquidity to raise the funds necessary for their upcoming Phase 2 trial in Q3 2026. 4. Financial Necessity The reason GANX is maintaining such a large ATM is their "burn rate." * The "Going Concern" Risk: In their Q3 2025 filing, auditors noted a "going concern" risk because their cash only lasted into early 2026. * The Solution: The $35.5M ATM, combined with a previous $7M raise, is designed to bridge the gap to late 2026 or early 2027. Summary of Offering Impact | Feature | Detail | |---|---| | Total ATM Limit | $35,530,980 | | Current Status | Active (ongoing sales likely during high-volume weeks) | | Primary Goal | Fund Phase 2 trial launch (Q3 2026) | | Investor Risk | Continued "sell-side" pressure on green days | Next Step: The actual number of shares sold through the ATM so far will be revealed in their March 26 earnings report.
Whats happening with GANX ? Dip after news ?
$GANX Their drug has shown promise in reversing Parkinson’s disease. They are in Phase II and are presenting data any day now. Within only 90 days, most patients are scoring better on motor skills tests. The annual revenue for a good Parkinson’s drug could be more than $1 Billion. The current market cap is only 100 Million.
People looking at GANX for this week?
GANX thoughts? - did some minor dd and seems like they are burning cash heavily and last time good news happened it pumped and dumped immediately.
While not Pennies, I’m praying for GANX to hold good news when they present their findings on the 17th. It’s one of those biotech cases that may truly work. Oftentimes there’s plenty of bullshit biotech stocks, and anyone with a brain can read through and realize that a good chunk of these companies are “fluffing” their findings for stock value, but this particular one holds a lot of promise towards success and closer to a cure for Parkinson’s
GANX is the biggest piece of shit ever just pure lateral movement
Here are the research reports. Gain Therapeutics(GANX): KOL Reports : GT-02287 Shows Signs of Disease Modification https://gaintherapeutics.wordpress.com/2026/01/14/gain-therapeuticsganx-kol-rpeorts-gt-02287-shows-signs-of-disease-modification/
Look into SLS, GANX, IBRX, and ASPI
Look at Gain Therapeutics ($GANX). First small molecule drug that has been able to reverse Parkinson's and they present data in 2 weeks at AD/PD. Nobody has ever heard of them and these are in patient results. https://www.reddit.com/r/pennystocks/s/TscnH8yA9A
Watching $GANX closely. Early signs of disease-modification, but still waiting on more data.
Im buying options in GANX. Im hoping that right now being sandwiched between two announcements will create some volatility
View in your timezone: [Feb 25, 6:20 PM GMT][0] [0]: https://timee.io/20260225T1820?tl=%24GANX%20%E2%80%93%20Massive%20Parkinson%E2%80%99s%20Breakthrough%3F%20Watch%20Tomorrow%20%26%20March%2017-21
View in your timezone: [Feb 25, 6:20 PM GMT][0] [0]: https://timee.io/20260225T1820?tl=%24GANX%20%E2%80%93%20Massive%20Parkinson%E2%80%99s%20Breakthrough%3F%20Watch%20Tomorrow%20%26%20March%2017-21
GANX presenting to Oppenheimer next week. Hopefully gets good word out in the investing community.
I think you’re low. With the data for Parkinson’s which likely links to other diseases, at this stage pre phase 2 is $500M. It’s showing acute symptom relief with “disease modifying potential”. You couple that with the Magellan platform for GANX and you’re looking by at $1b + buyout. I wouldn’t be surprised if they have an offer on the table right now, and competing bids. They’re in a crunch, so the only thing that work for them is competing bids to drive up price. This would make sense as to why phase 2 has been delayed. Why run phase 2 with a buyout/partnership looming? With other disease test preclinical moving into phase 1 soon. the current drug is the first from the Magellan platform and shows major promise. 1.5-2b after factoring in CVR.
I’m guilty I hold on to speculative issues. My latest is GANX. I have several good friends with Parkinson’s. Hope GANX pans out.
Yes, there should be an update very soon. They filed the IND in December. Also, they just released a new corporate update... some good info in there: [https://gaintherapeutics.com/wp-content/uploads/2026/02/GANX-February-2026-Corporate-Deck-Final4.pdf](https://gaintherapeutics.com/wp-content/uploads/2026/02/GANX-February-2026-Corporate-Deck-Final4.pdf)
I'd say I'm committed to what the data is saying, but I know what you mean. GANX has been an extreme example of biotechs where good news is sold. But this market behavior only lasts so long. Eventually, when the ripples of the data start reaching the broader science world, I think that's where this changes. Unless it happens sooner via partnership/buyout, which I think is likely. Either way, I think we're just a few months away from this coming to a head. The world doesn't know yet. I was an investor in Mind Medicine a few years back. It was too early, but I believed (and believe) in the approach. Glad it is on an uptrend now. Totally forgot about it. Looks like daily RSI is in the overbought zone, so I might look for a pullback to take a small position again. But I'm limiting my biotech exposure. GANX has giant promise, so that's where most of my biotech allocation is. COYA is another that is at an attractive price right now, but my position there is much smaller. But I'll keep an eye on DFTX-- thanks.
Again buying some GANX for the rally of today!
All the fundamentals can be right, but if they have no cash Investors get diluted. * **As of Sept 30, 2025 (Q3 10-Q):** **31,600,000 shares** outstanding. * **As of Jan 16, 2026 (Real-Time):** **38,462,000 shares** outstanding. * **The Total Added:** **\~6,862,000 new shares. 22% dilution.** **They are burning through around 1.5million a month just operations and continuing phase 1B. I do think the bottom is around $1.4 - $1.6 because everyone is expecting some kind of partnership by march / april. I am leaning towards April personally. I have been following your posts for a while, and invested some before the runup in December and then lost much more on the drop. Idk I am probably going to add more, the data is strong, but my only concern is with the** Elevated Liver Enzymes even though they said it was transient, we don't have long term data. If you remember **Venglustat**, Sanofi’s high-profile Parkinson’s drug that famously failed in Phase 2 back in **2021** shows really promising phase 1 results. Granted these two drug work very differently, but I think BioPharma is more risk averse now and want more data. They can wait it out, they have nothing to lose, while GANX keeps diluting shareholders to keep operations going.
Can you monkeys please use your monkey powers to buy into GANX? It's for your grandpa's mental health so he can still remember your name ... Or grandma when she goes to pinch your cheeks and says "you're not my grandson's boyfriend are you????" Ganx has the cure!!! Lol
What is your guys view on GANX?
It’s really hard when the data is strong but the price goes down, which is common in biotech over shorter time periods. Some of my most successful investments have resulted from buying when the dropping price causes fear. Which is a hard time to buy, especially if one doesn’t have conviction. I’d just say hang in there. If I wasn’t already irresponsibly heavy in my GANX investment, I’d be adding here.
I continue to lose money with GANX. The science seems strong though.
I'm going with ASTS and GOOG (duh), AMPX, GANX, IREN all only if there's no major once in a lifetime event. Unfortunately, there has been a reversal today, all packaged food companies (many of which were -50% their 5 year highs as of the last few weeks) shot up, indicating people are seeking safe havens. I get the feeling this year's going to be wild.
In what way, shape, or form, has GANX been transparent with the data??! The ONLY biomarker released was GluSph. Nothing about Nfl, alpha-synuclein, lysosomal or mitchondrial markers! So this is bs to say they are transparent.. And if these biomarkers were favorable, they'd be released.
GANX participating and presenting at JPMorgan conference next week, I think that's news as before it was only known that they would be attending
At the risk of beating a dead horse, I'm still a little confused about this - I understand that average investors might not pick up on the nuances of certain scientific updates but good news is still good news. I've seen other biotech companies release positive data updates that also require deep knowledge to truly understand the details, but investors get the gist and if the takeaway is that the data is positive, the stock doesn't plummet like I've seen it happen twice now with GANX. Would love to get your pov on this!
You have to look at the recent conference poster plus today's slide to see the data you want. I added the poster piece under today's data in this info. At the end. Hope this helps. Gain Therapeutics(GANX): Maxim $7 Buy 1/6/26 : KOLs are Positive https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-maxim-7-buy-1-6-26-kols-are-positive/
I added back in the three patients who didn't do the exit lumbar test. Plus I sorted out the three non responders. I think they know why. I have the data at the end of this report if your interested. Gain Therapeutics(GANX): Maxim $7 Buy 1/6/26 : KOLs are Positive https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-maxim-7-buy-1-6-26-kols-are-positive/
Lol. Well, that makes two of us with serous money in GANX.
Gain Therapeutics(GANX): BTIG Buy 1/6/26 : KOL Event BTIG Report https://gaintherapeutics.wordpress.com/2026/01/06/gain-therapeuticsganx-btig-buy-1-6-26-kol-event/
I think GANX should not do anymore public events at all since the market reaction is always like this. No matter if it's good or bad news, to the south we go. I actually had an alarm set for yesterday to sell them all and watch from the sideline what happens, but for some reason I decided to go against my initial instinct and ended up holding. Now I'm pissed at the stupid market and most importantly to myself. I'm sure as hell going to sell before the next news event I guess it will bounce back a little bit tomorrow but will take time to get back to 3 which is my average price at the moment
30% of my portfolio is in GANX, and my portfolio is pretty big.
Think GANX, SLS and ASBP is just too important to ignore. This is going to be rocky... whatever... NFA... I bought some more. (Not banking on my entire portfolio with these buys) Also me: 
Is GANX dead...? Thought today would be better.
13/15 GANX patients had MDS-UPDRS of 4; 2 were much lower (potential outliers), that puts the 2.2 average score into a new perspective
https://www.stocktitan.net/news/GANX/gain-therapeutics-highlights-biomarker-evidence-supporting-disease-kug2co9rch67.html
Some positive news on $GANX Gain Therapeutics just came out, small group and early trial but promising nonetheless, in case anyone wants to monitor today https://finance.yahoo.com/news/gain-therapeutics-highlights-biomarker-evidence-120000261.html
IMRX and GANX have attractive entry points rn
SLS still is a gamble, there is a real case that current valuation is fair/high and people banking on something happening during JP Morgan event will probably be disappointed which could cause a (big) drop VKTX, IMRX and GANX have way more room for steep rises in the coming weeks imo
What's the deal with GANX rn, should i not be worried about a little dip before tomorrow's KOL?
What's the speculation for the GANX KOL event tomorrow?
SLS for next 6 months then GANX with SLS gains.
Sanofi is a big player in Gaucher and Enzyme Replacement Therapy. They are moving up to my most likely acquirer but Merck is also at the table. Gain Therapeutics(GANX): Final Update before Phase 1b data at January 6th KOL Event https://gaintherapeutics.wordpress.com/2025/12/31/gain-therapeuticsganx-final-update-before-phase-1b-data-at-january-6th-kol-event/
There are 50M shares fully diluted to use for any calculations. Typically with a 3 dollar stock getting 3-5x market cap is considered good. That would be in the $500m to $750m range. But here is what I think. This is a phase 2 ready asset that they have filed the clinical plan for. A big pharma could start that trial in 2 months. So the first drug that can slow down, stop and perhaps reverse Parkinsons? Even at the Phase 2 stage it has to be worth at least a billion or $20/share. Now they have 15 companies they have been working with and several that they are only sharing the latest data with so far. I dont see a company like Merck, Roche or JNJ allowing someone else to own it just because on money. Sanofi also is a big player in Gaucher and this drug(see latest data in these reports) could play well in that multibillion a year market. Gain Therapeutics(GANX): Final Update before Phase 1b data at January 6th KOL Event https://gaintherapeutics.wordpress.com/2025/12/31/gain-therapeuticsganx-final-update-before-phase-1b-data-at-january-6th-kol-event/
I like to smoke a joint and put some music on. Then I find some medial task or hobby that I can do while my mind wanders on to what the future will look like in 10 years. I try to think of what industry will be huge. Things that haven't already "popped off" like AI for example. In fact using the big winners of today can help predict what the winners of the future will be. What will be huge if AI succeeds? Personal EMP protective suit perhaps? Or maybe that little Antimony company in a geographically strategic location? And if AI fails? We'll shit maybe Ford motor company makes a comeback and we all have to take our asses back on the freeway. This is just an example of a brainstorm, have a pen and paper and write down some of these ideas.... Personal emp protective suit into googs, see if it exists or if anyone already makes something like that. Can I invest in that company? Manage risk and monitor debt/dilution/PRs By doing this I got onto rklb july/Aug 2024 around 5$ and at one point held 19 jan15'25 8$ call contracts for about 2500$ down...I sold at 7500$ and bitched out. Clearly I'm a rookie but the method is pure and my conviction in my picks grows stronger...conviction is easier to have when risk is managed. Currently buying GANX. Cheers
I've had my eyes on this for a while now. This recent news has me looking at it very positively. My only concern is possible dilution since, this shows, they have enough cash on hand for a few more months at their current pace. I would assume there would be some sort of acquisition taking place (GANX being acquired) if they aren't diluting. https://preview.redd.it/ow89o1u69lag1.png?width=770&format=png&auto=webp&s=6f28b938f5d3474716d4a7b1ceca40101bbca6a7
I would love to post about it. I just don’t think I know the science/biology well enough or feel confident enough to post as a subject matter expert. I’ve been invested in $GANX for about a year and have read as much as I can get my hands on but still shy to put myself out there. There are only so many from the general public that can speak to the biology like Correct Proposal or Micorcap. I also think it’s why the company is still flying under the radar.
I'm not disputing whatever is in this post or qhether GANX is a good investment or not, but everytime this stock gets posted its always you two (OP and the other guy commenting). Just seems suspicious
If i can offer a different perspective.. i suspect that many redditors deeply dislike the flood of AI slop posts in this sub (I’m among them and I’ve blocked tons of accounts to try to filter the noise). By formatting your post to appear like a chat-gpt output (bold headers, lots of dashes, no synthesis), it’s unclear which pieces are your convictions and which are AI. You may have done a ton of work, but it really does look like copy/paste nonsense. I believe in this company, and i bought a few hundred shares of GANX in late October (my average is about 2.5 now tho). However, endless AI slop posts constantly rattling on about a stock’s potential are becoming more prevalent; these can sometimes serve as a real red flag for prospective buyers. For the record - I don’t have any ideas of solution to fix the problem (aside from individually blocking spam-looking posts), but i sorta understand why somebody might have an averse reaction to the medium (not the message, im fully supportive of Gains work). Just one perspective from a very casual trader!
Who still holding GANX?
GANX is not in a good cash position, they are looking for a buyout partner. All eyes on Jan 6 right now
98% chance that GANX will be owned or will have partnered with a large pharma by mid 2026.
Great post. Looking forward to KOL event next week. Gain Therapeutics(GANX): Final countdown to Phase 1b data at January 6th KOL Event https://gaintherapeutics.wordpress.com/2025/12/20/gain-therapeuticsganx-final-countdown-to-phase-1b-data-at-january-6th-kol-event/
RemindMe! 345 days I take my SLS profits and shift to GANX then
is $GANX rippin' today?
Great info. We should get the data we expected in Q4 and then extended data at AD/PD. Gain Therapeutics(GANX): Final countdown to Phase 1b data at January 6th KOL Event https://gaintherapeutics.wordpress.com/2025/12/20/gain-therapeuticsganx-final-countdown-to-phase-1b-data-at-january-6th-kol-event/
Crazy man. I got stopped out last week with a very small loss on RVPH but MIST and GANX really fucked me up. I didn't lose a lot of money, but I lost my profits. Should have set a tighter stop loss which sucks too. Biotech can be a slippery slope for sure.
I’ve seen a fair amount of DD on GANX but the fact that the company is literally called Gain is the most convincing.
GANX is the only good one i have seen here
Came here to say GANX and FEMY are the two I am most strongly behind.
$GANX so much potencial. DYOR
See also PTRN, NAVN MIAX was one of the most successful IPOs this year, don't see that going away anytime soon I'm going to bet with money that ANET and SKYT do well. Haven't done it yet. GANX is my only bag on this list, asymmetric risk bet, especially with the crazy sell off last week. They'll get bought out this year, calling it now
Depends on the circumstances. Impossible to time perfectly, but momentum trading allows you to snipe on the upside. I watch a few tickers that are volatile TGB & GANX have made money for me lately. Others I keep long term and just buy on a regular schedule GLD has done well for me. I do own VOO & SCHD as stalwarts.
Depends on what you consider going to the moon. For me that probably means a triple in a year. Not bags, as I am tripled already, but GANX could triple or lose 2/3 soon. As in next 3 months. Debating whether to sell part of my position and freeroll. I also like HROW to double, and CRDOF could easily double. If you asked me which of my holdings would be most likely to double this year I would say CRDOF. I already got a triple off it this year.
Now that we now know how impressive the biomarker improvement was we can look forward to seeing more data at upcoming KOL event. Gain Therapeutics(GANX): ROTH MKM Thought on Phase 1b data: Raising price target to $10 https://gaintherapeutics.wordpress.com/2025/12/19/gain-therapeuticsganx-roth-mkm-thought-on-phase-1b-data-raising-price-target-to-10/ joeiniowa@gmail.com
GANX has insane short squeeze potential, 50% of shares traded yesterday were shorts. Already 6M over daily volume average and stock just took a 14% dip from daily high. Needs buying pressure. Could very well see $3.25 by EOD
GANX short squeeze